
Background The pericapsular nerve group (PENG) block is an increasingly utilized regional anesthesia technique for pediatric hip surgery. Dexamethasone prolongs the duration of peripheral nerve blocks and can be administered either intravenously or perineurally; however, the comparative pediatric evidence on postoperative analgesia and metabolic effects with these two routes is limited. Questions/purposes (1) Does perineural dexamethasone prolong the time to first rescue opioid analgesia compared with intravenous dexamethasone when used as an adjunct to PENG block in pediatric hip surgery? (2) Does perineural dexamethasone reduce postoperative opioid consumption and pain intensity? (3) Does the route of dexamethasone administration influence postoperative inflammatory markers and blood glucose levels? (4) Is perineural dexamethasone associated with an increased risk of neurologic complications? Methods This randomized, blinded trial was conducted at a single urban tertiary university referral center in Poznań, Poland, providing subspecialty pediatric orthopaedic care. Parents and caregivers, treating anesthesiologists, surgeons, and outcome assessors were unaware of group allocation. Between February 2025 and March 2026, we assessed 72 children scheduled for elective reconstructive hip surgery. Children age 3 months to 6 years with developmental dysplasia of the hip or neurogenic hip displacement associated with cerebral palsy were considered potentially eligible. Of the 72 children assessed, 92% (66) met the eligibility criteria. Nine percent (6 of 66) of these children were not enrolled because four families declined participation and two declined regional anesthesia. The remaining 83% (60 of 72) were randomized. No participants were lost during the 48-hour in-hospital follow-up or had incomplete outcome data, and all 60 were included in the analysis. The perineural and intravenous groups had mean ± SD ages of 4.8 ± 1.2 and 5.2 ± 1.1 years, respectively; 47% (14 of 30) and 50% (15 of 30) were boys, and 70% (21 of 30) and 73% (22 of 30) had developmental dysplasia of the hip. The remaining children had neurogenic hip displacement associated with cerebral palsy. There were no clinically important between-group differences in these baseline characteristics. All patients received standardized spinal anesthesia and multimodal postoperative analgesia consisting of paracetamol 15 mg/kg and metamizole 15 mg/kg every 6 hours, ibuprofen 10 mg/kg every 8 hours, and rescue nalbuphine 0.1 mg/kg for Face, Legs, Activity, Cry, Consolability (FLACC) scores of ≥ 4. The primary endpoint was time to first rescue opioid analgesia within 48 hours. Secondary endpoints included total opioid consumption, postoperative pain scores, inflammatory markers (neutrophil-to-lymphocyte ratio [NLR] and platelet-to-lymphocyte ratio [PLR]), blood glucose levels, and peripheral nerve injury assessed at 12, 24, and 48 hours. Results We found no difference between the perineural and intravenous dexamethasone groups in time to first rescue opioid analgesia after adjustment for age, body weight, and duration of surgery (HR 0.56 [95% confidence interval (CI) 0.28 to 1.08]; p = 0.08). Perineural dexamethasone reduced total opioid consumption during the first 48 postoperative hours (mean ± SD 0.131 ± 0.048 versus 0.225 ± 0.053 mg/kg morphine milligram equivalents (MMEs), mean difference -0.095 mg/kg [95% CI -0.121 to -0.068]; p < 0.001), corresponding to approximately 42% lower mean opioid consumption and an absolute difference of approximately 1.9 mg MME for a child weighing 20 kg. No differences were observed in NLR or PLR between groups, whereas mean ± SD blood glucose levels were lower in the perineural dexamethasone group at 12 hours (112 ± 17 versus 139 ± 20 mg/dL; p < 0.001) and 24 hours (112 ± 14 versus 134 ± 25 mg/dL; p < 0.001). No neurologic complications occurred in either group during the 48-hour follow-up period. Conclusion After adjustment for age, body weight, and duration of surgery, we found no difference between perineural and intravenous dexamethasone in time to first rescue opioid analgesia. Perineural dexamethasone was associated with lower opioid consumption and lower early postoperative blood glucose levels. Larger multicenter studies are needed to evaluate these findings in pediatric regional anesthesia. Level of Evidence Level I, therapeutic study.
BACKGROUND: Macroscopic venous tumor thrombus (VTT) is a rare but aggressive manifestation of osteosarcoma that poses substantial challenges for both surgical management and systemic disease control. Our previous work characterized its frequency, radiographic features, and adverse prognostic association, particularly in pelvic osteosarcoma; however, surgical management was heterogeneous. The patient-level outcomes achieved after a standardized multidisciplinary treatment approach and the association between VTT resection strategy and postoperative oncologic outcomes remain unclear. QUESTIONS/PURPOSES: (1) What were the oncologic outcomes of patients with osteosarcoma with macroscopic VTT treated under a standardized treatment algorithm incorporating aggressive surgical resection? (2) Did the choice of VTT resection strategy affect oncologic outcomes? METHODS: We screened the records of 39 patients with treatment-naive osteosarcoma and macroscopic VTT identified on imaging who were treated according to a standardized multimodal treatment algorithm between 2019 and 2024. This algorithm consisted of standardized multimodal imaging at diagnosis to detect and characterize VTT. After biopsy confirmation, patients received four-agent neoadjuvant chemotherapy, preoperative inferior vena cava filter placement when technically feasible, and repeat imaging to reassess the resectability of both the primary tumor and VTT. Surgery was undertaken only when both lesions were considered resectable. VTT involving peripheral venous branches or completely occluded and enlarged major veins was managed with en bloc venous resection, whereas thrombectomy was performed for VTT involving patent or partially patent major veins. Postoperative chemotherapy was initiated 2 to 3 weeks after surgery. After excluding one patient without pathologic confirmation of the macroscopic VTT, two patients in whom en bloc resection of the primary tumor was not achieved, and seven patients who did not receive postoperative chemotherapy, 29 patients were included in this retrospective analysis. The study population was young (mean ± SD age 16 ± 7 years), with a slight male predominance (17 of 29 patients), and primary tumors were distributed between the extremities (16 of 29) and pelvis (13 of 29). More than half of the patients presented with metastatic disease (16 of 29), most VTTs involved major venous trunks (22 of 29), and 20 of 29 patients had < 90% tumor necrosis after neoadjuvant chemotherapy. Given the high risk of early progression in these patients, progression-free survival (PFS) was selected as the primary endpoint. Secondary endpoints included overall survival (OS), local recurrence-free survival (LRFS), and metastasis PFS (MPFS). RESULTS: Patients treated under the standardized algorithm had limited durable disease control, with disease progression in 26 of 29 patients, a median PFS of 7 months (95% confidence interval [CI] 0 to 16), and an estimated 2-year OS of 60%. Patients with localized disease had longer PFS (median 13 months [95% CI 8 to 19] versus 5 months [95% CI 4 to 5]; p = 0.046) and MPFS (median 13 months [95% CI 8 to 19] versus 4.6 months [95% CI 4 to 5]; p = 0.04) than those with metastatic disease. There were no differences in OS (not reached versus median 32 months [95% CI 10 to 54]; p = 0.52), PFS (median 11 months [95% CI 0 to 31] versus 6 months [95% CI 3 to 9]; p = 0.62), LRFS (median 21 months [95% CI 9 to 34] versus 61 months [95% CI 2 to 120]; p = 0.54), and MPFS (median 13 months [95% CI 0.3 to 25] versus 8 months [95% CI 3 to 13]; p = 0.24) between patients who had thrombectomy versus en bloc venous resection. CONCLUSION: Despite a standardized multidisciplinary approach incorporating perioperative chemotherapy and aggressive resection of both the primary tumor and macroscopic VTT, progression remained frequent, and durable disease control was uncommon. Among these 29 selected patients, VTT resection strategy-thrombectomy versus en bloc venous resection-was not detectably associated with oncologic outcomes, although the two groups were not directly comparable. Surgeons should recognize that osteosarcoma with macroscopic VTT is a rare, highly aggressive condition for which current treatment modalities seldom achieve a cure and should carefully balance the potential oncologic benefit of aggressive surgery against its morbidity. Future prospective multicenter studies should refine patient-level selection criteria and directly evaluate the incorporation of adjuvant radiotherapy into this standardized treatment algorithm. Novel systemic therapies should also be investigated to improve control of metastatic and rapidly progressive disease. LEVEL OF EVIDENCE: Level III, therapeutic study.